Cinnamon and early postmenopause symptoms: what a randomized clinical trial shows

After two months, the women assigned to the cinnamon group reported less intense overall symptoms compared to the placebo group. The mean score was 13.95 ± 4.16 with cinnamon and 16.64 ± 4.16 with placebo. The difference reached statistical significance after adjusting for baseline values: P = 0.01.

In practical terms, the estimated effect size was 0.65. This standardized value indicates a moderate difference between the groups in the context of this small sample; however, its 95% confidence interval, ranging from 0.12 to 1.17, remains wide. The psychological domain showed a difference in favor of cinnamon, with P = 0.006 and an effect size of 0.74, with a 95% confidence interval from 0.21 to 1.27. There is insufficient data available in the verified text to attribute these results to cinnamaldehyde, eugenol, or other specific components.

The main value of this work is methodological: it studies people, uses a placebo, and limits the influence of expectations through a triple-blind design. This makes the comparison more informative than an uncontrolled observation. Furthermore, it evaluates a complete product rather than an isolated molecule; the result therefore concerns that specific capsule, that dosage, and that duration.

The data is relevant because it shows that the profile of a plant-based preparation can also be studied at a clinical level. However, it does not clarify which component of cinnamon might be involved, nor does it demonstrate that all spices, extracts, or cinnamon-based supplements produce the same effect. This step requires interpretive caution.

The trial was small, analyzed 59 people, and lasted for just two months. Therefore, it can detect an initial difference, but it cannot define the duration of the potential effect, long-term safety, or results in larger and more diverse groups. Furthermore, the outcomes were based on questionnaires completed by the participants, which are useful for measuring the experience of symptoms but are not equivalent to an objective biological indicator.

The study by Refaei and colleagues does not demonstrate that cinnamon cures menopause, permanently alters hormones, or replaces medical treatments. It also does not demonstrate a causal relationship between a single molecule of the spice and the change in scores. The species, extraction method, and product standardization are essential aspects for correctly comparing future studies.

Partial clinical confirmation comes from the trial by Koliji and colleagues [1]. In 105 postmenopausal women, divided into groups receiving cinnamon, Vitex agnus-castus, and a placebo, 400 mg of the product in capsule form was evaluated over two to three months regarding sexual function. The overall score improved in the cinnamon group compared to the placebo. This supports the premise that a cinnamon-based product can be studied for outcomes reported by postmenopausal women. The confirmation is direct in terms of population and design, but it concerns sexual function, not the overall symptom score.

The systematic review by Maunder and colleagues [2], which included 158 publications on complementary therapies for menopause, places results like those of Refaei in a more cautious framework: many signals are promising, but the overall certainty for many options remains low or very low. This is indirect confirmation of the need not to generalize from a single trial; it does not specifically confirm the efficacy of cinnamon. Furthermore, the meta-analysis by Moridpour and colleagues [3], covering 24 trials on type 2 diabetes, shows that the outcomes of cinnamon depend on the population, formulation, and measured result. This provides indirect support for the need to distinguish between products and contexts, rather than serving as proof regarding menopausal symptoms.

Studies on other clinical outcomes show inconsistent results. In 25 postmenopausal women with type 2 diabetes, Vanschoonbeek and colleagues [4] did not observe improvements in insulin sensitivity, glucose tolerance, or lipids after six weeks of 1.5 grams per day of Cinnamomum cassia. This result does not directly contradict the scores on menopausal symptoms, but it indicates that an effect cannot be automatically extended to different metabolic parameters.

In another trial, Wickenberg and colleagues [5] studied 21 people with impaired glucose tolerance; 17 completed 12 weeks with 12 grams per day of Cinnamomum cassia. No significant changes emerged in insulin sensitivity, glycated hemoglobin, or liver enzymes. These differences between species, doses, populations, and measured outcomes reinforce the need for caution. No directly conflicting evidence sufficiently relevant to overall postmenopausal symptoms has been identified; this does not prove the absence of contrary results.